KEYTRUDA 25 mg/mL Concentrate for Infusion
Quick summary: KEYTRUDA (pembrolizumab) 25 mg/mL is a concentrate for solution for infusion used in cancer treatment. It is given by intravenous infusion under medical supervision, and the exact schedule, vial size, and handling...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary: KEYTRUDA (pembrolizumab) 25 mg/mL is a concentrate for solution for infusion used in cancer treatment. It is given by intravenous infusion under medical supervision, and the exact schedule, vial size, and handling instructions should be checked in the official product information.
This page gives a practical overview of what it is, how it is administered, storage basics, and what to verify in the SmPC or with a healthcare professional.
Medical disclaimer: This article is for general information only and does not replace the official SmPC, package leaflet, or advice from an oncologist, pharmacist, or infusion team. Do not use this page to self-diagnose, self-treat, or change any prescribed cancer treatment.
What is KEYTRUDA 25 mg/mL concentrate for solution for infusion?
KEYTRUDA is the brand name for pembrolizumab, a monoclonal antibody used in cancer treatment. It is administered as an intravenous infusion and is intended to help the immune system recognize and attack cancer cells.
The original content notes that KEYTRUDA is used for several cancers, including melanoma, lung cancer, and head and neck cancers. The exact approved use depends on the cancer type and the treatment plan chosen by the oncology team.
How KEYTRUDA is given
KEYTRUDA is infused into a vein in a healthcare setting. The infusion is carried out under medical supervision so the team can monitor the patient during treatment and respond if any infusion-related reaction occurs.
The original content states that infusion time is typically around 30 minutes, although this can vary depending on the patient and the treatment protocol.
What is usually checked before and during infusion?
- General health status before treatment
- Vital signs and clinical monitoring during infusion
- Observation after infusion for delayed reactions or side effects
What is KEYTRUDA used for?
The original content mentions use in melanoma, non-small cell lung cancer, head and neck cancers, and other malignancies. Because cancer indications can differ by country and by product information updates, the official SmPC should always be checked for the current approved uses.
If you are reviewing this medicine for a specific cancer type, a doctor or pharmacist can confirm whether the indication matches the local label and the patient’s treatment plan.
Price information
The original content gives approximate cost ranges for KEYTRUDA infusions and notes that prices can vary by provider, location, dose, and insurance coverage. These figures are highly variable and should be treated only as broad estimates.
For practical planning, patients and caregivers should verify the final cost with the treating hospital, pharmacy, insurer, or patient support service. Financial assistance options may be available through healthcare systems or treatment centers.
Storage and handling
Proper storage is important to help maintain product quality. The original content states that KEYTRUDA should be stored refrigerated at 2°C to 8°C and should not be frozen.
It also notes that the vial should be protected from direct light and kept out of reach of children. Any handling, dilution, or disposal should follow the official product instructions used by the healthcare team.
| Topic | What the original content says | What to verify |
|---|---|---|
| Infusion route | Intravenous infusion | Exact administration instructions in the SmPC |
| Typical duration | Around 30 minutes | Whether the schedule differs for the patient’s regimen |
| Storage temperature | 2°C to 8°C | Local handling and stability instructions |
| Vial sizes | 100 mg/4 mL and 200 mg/10 mL mentioned | Available presentations in the local market |
What is the SmPC and why does it matter?
The Summary of Product Characteristics, or SmPC, is the official technical document for healthcare professionals. It contains information on indications, administration, storage, and safety details.
For KEYTRUDA, the SmPC is the best source to confirm the current formulation, approved uses, and handling instructions. Patients can also ask their oncology team to explain any part of the leaflet or SmPC that is unclear.
Vial size and presentation
The original content mentions vial presentations such as 100 mg/4 mL and 200 mg/10 mL. These are single-use vials, and any unused product should be handled according to healthcare facility procedures.
Because presentations can vary by market, it is sensible to confirm the exact vial size on the pack, in the SmPC, or with the dispensing pharmacy.
Possible side effects and monitoring
The original content mentions fatigue, nausea, and skin reactions as examples of adverse effects. It also emphasizes the need for close monitoring during treatment.
Patients should report any new or worsening symptoms to their oncology team promptly. The treatment team can decide how to assess and manage symptoms based on the full clinical picture.
Frequently asked questions about KEYTRUDA
▸ What is pembrolizumab 25 mg/mL?
Pembrolizumab is the active substance in KEYTRUDA. The 25 mg/mL strength refers to the concentration of the concentrate used to prepare the infusion.
▸ What is KEYTRUDA infusion used for?
The original content says it is used in the treatment of several cancers, including melanoma, non-small cell lung cancer, and head and neck cancers. The exact approved use depends on the official product information.
▸ How long is a KEYTRUDA infusion?
The original content states that a typical infusion lasts about 30 minutes, although the exact duration may vary depending on the treatment plan and patient monitoring needs.
▸ How much is one KEYTRUDA infusion?
The original content gives broad price estimates and notes that costs vary widely by dose, provider, insurance, and location. The treating hospital or pharmacy can provide the most accurate estimate.
▸ What storage temperature is recommended?
The original content states that KEYTRUDA should be stored at 2°C to 8°C and should not be frozen. Always follow the official leaflet or local handling instructions.
▸ Where can I check the official details?
The SmPC and package leaflet are the best sources for official information on indications, administration, storage, and safety. A pharmacist or oncology team can help interpret them.
Safety reminder: Cancer medicines should only be used and monitored by qualified healthcare professionals. If you have questions about infusion timing, storage, side effects, or cost, confirm the details with the treating team or the official product leaflet rather than relying on general web information.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.